Donate
Families and researchers are counting on you !

A look back at Myology 2022 

Published at
Myology 2022 congress

During four days, from 12 to 15th of September, researchers, clinicians and myology experts have attended the seventh International Congress of Myology, organized by AFM-Téléthon, in Nice, France. A good opportunity to exchange and share knowledge about myology and innovative therapies. Let’s have a look back at Myology 2022 with our researchers’ video interviews.

This international congress brought together around 800 experts in the field of Myology and neuromuscular diseases from all over the world (35 countries). More than 70 international speakers have taken the floor during 18 plenary and parallel sessions. 

“In 2019, at our last Myology meeting in Bordeaux, we observed the first instances of innovative therapies for neuromuscular diseases, in particular the first gene therapy. Since then, despite the pandemic that shook the world, research has continued to accelerate, and three years after our last meeting we see increasing numbers of trials and results.
More than ever, myology is at the cutting edge of therapeutic innovation, at the forefront of a medical revolution to serve as many patients as possible! For patients and their families receiving these first therapies, the diagnosis now comes with a treatment proposal, which changes everything!”
said Laurence Tiennot-Herment, President of AFM-Téléthon.

Elisabeth McNally, co-president of Myology 2022, about the congress and the progress in research

Access to this content has been blocked to respect your choice of consent.
To access this content, you must modify your preferences and accept at least one of the following services: ou
Change my preferences

 

Terrence Partridge, about Duchenne Muscular Dystrophy

Access to this content has been blocked to respect your choice of consent.
To access this content, you must modify your preferences and accept at least one of the following services: ou
Change my preferences


Federica Montagnese, about clinical trials

Access to this content has been blocked to respect your choice of consent.
To access this content, you must modify your preferences and accept at least one of the following services: ou
Change my preferences

 

Francesco Muntoni about SMA and DMD

Access to this content has been blocked to respect your choice of consent.
To access this content, you must modify your preferences and accept at least one of the following services: ou
Change my preferences

 

One word to describe the congress "Myology 2022"

Access to this content has been blocked to respect your choice of consent.
To access this content, you must modify your preferences and accept at least one of the following services: ou
Change my preferences